MedTrace Logo

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

NCT00418743 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2010-03-09

No results posted yet for this study

Summary

The purpose of this study is to determine treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Conditions

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • Groupe Francais De Pneumo-Cancerologie

    lead OTHER

Principal Investigators

  • Christos CHOUAID, Professor · Groupe Francais De Pneumo-Cancerologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2010-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418743 on ClinicalTrials.gov